MARKET

CABA

CABA

Cabaletta Bio, Inc.
NASDAQ
3.820
-0.060
-1.55%
Pre Market: 3.800 -0.02 -0.52% 05:11 05/12 EDT
OPEN
3.875
PREV CLOSE
3.880
HIGH
4.060
LOW
3.710
VOLUME
39
TURNOVER
0
52 WEEK HIGH
4.230
52 WEEK LOW
1.240
MARKET CAP
425.26M
P/E (TTM)
-1.8184
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CABA last week (0504-0508)?
Weekly Report · 1d ago
Cabaletta Bio (CABA) Is Up 34.2% After Early RESET-PV Data And US$150M Equity Raise
Simply Wall St · 4d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cabaletta Bio (CABA), Inspire Medical Systems (INSP) and UnitedHealth (UNH)
TipRanks · 6d ago
Assessing Cabaletta Bio (CABA) Valuation After 10 Year Cellares Supply Deal And Upcoming Rese Cel Data
Simply Wall St · 6d ago
Cabaletta Bio Maintained at Buy as Emerging Rese-cel Data Support Preconditioning-Free Potential; $13 Price Target Reaffirmed
TipRanks · 05/05 01:35
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 05/04 17:06
Cabaletta Bio Shares Rise After $150M Underwritten Offering Prices
Dow Jones · 05/04 14:38
Global Business Travel Group Posts Upbeat Q1 Results, Joins Cabaletta Bio, Aura Biosciences And Other Big Stocks Moving Higher On Monday
Benzinga · 05/04 13:54
More
About CABA
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.

Webull offers Cabaletta Bio Inc stock information, including NASDAQ: CABA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CABA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CABA stock methods without spending real money on the virtual paper trading platform.